AbCellera Biologics Inc.
ABCL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $28,833 | $38,025 | $485,424 | $375,203 |
| % Growth | -24.2% | -92.2% | 29.4% | – |
| Cost of Goods Sold | $0 | $0 | $66,436 | $45,516 |
| Gross Profit | $28,833 | $38,025 | $418,988 | $329,687 |
| % Margin | 100% | 100% | 86.3% | 87.9% |
| R&D Expenses | $167,259 | $175,658 | $107,879 | $62,062 |
| G&A Expenses | $72,711 | $60,999 | $55,485 | $41,848 |
| SG&A Expenses | $85,490 | $75,179 | $66,755 | $48,761 |
| Sales & Mktg Exp. | $12,779 | $14,180 | $11,270 | $6,913 |
| Other Operating Expenses | $90,850 | $24,395 | $27,843 | $14,451 |
| Operating Expenses | $343,599 | $275,232 | $202,477 | $125,274 |
| Operating Income | -$314,766 | -$237,207 | $216,511 | $204,413 |
| % Margin | -1,091.7% | -623.8% | 44.6% | 54.5% |
| Other Income/Exp. Net | $114,371 | $63,178 | $22,588 | $14,736 |
| Pre-Tax Income | -$200,395 | -$174,029 | $239,099 | $219,149 |
| Tax Expense | -$37,538 | -$27,631 | $80,580 | $65,685 |
| Net Income | -$162,857 | -$146,398 | $158,519 | $153,464 |
| % Margin | -564.8% | -385% | 32.7% | 40.9% |
| EPS | -0.55 | -0.51 | 0.56 | 0.56 |
| % Growth | -7.8% | -191.1% | 0% | – |
| EPS Diluted | -0.55 | -0.51 | 0.5 | 0.48 |
| Weighted Avg Shares Out | 294,328 | 289,166 | 285,057 | 275,764 |
| Weighted Avg Shares Out Dil | 294,328 | 289,166 | 314,827 | 318,294 |
| Supplemental Information | – | – | – | – |
| Interest Income | $38,473 | $42,247 | $16,079 | $3,330 |
| Interest Expense | $0 | $0 | $4,045 | $5,225 |
| Depreciation & Amortization | $96,998 | $30,894 | $33,102 | $17,250 |
| EBITDA | -$204,148 | -$192,158 | $260,167 | $239,149 |
| % Margin | -708% | -505.3% | 53.6% | 63.7% |